C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease
- PMID: 16738034
- PMCID: PMC2104755
- DOI: 10.1136/thx.2006.059808
C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease
Abstract
Background: Although C-reactive protein (CRP) levels are increased in chronic obstructive pulmonary disease (COPD), it is not certain whether they are associated with adverse clinical outcomes.
Methods: Serum CRP levels were measured in 4803 participants in the Lung Health Study with mild to moderate COPD. The risk of all-cause and disease specific causes of mortality was determined as well as cardiovascular event rates, adjusting for important covariates such as age, sex, cigarette smoking, and lung function. Cardiovascular events were defined as death from coronary heart disease or stroke, or non-fatal myocardial infarction or stroke requiring admission to hospital.
Results: CRP levels were associated with all-cause, cardiovascular, and cancer specific causes of mortality. Individuals in the highest quintile of CRP had a relative risk (RR) for all-cause mortality of 1.79 (95% confidence interval (CI) 1.25 to 2.56) compared with those in the lowest quintile of CRP. For cardiovascular events and cancer deaths the corresponding RRs were 1.51 (95% CI 1.20 to 1.90) and 1.85 (95% CI 1.10 to 3.13), respectively. CRP levels were also associated with an accelerated decline in forced expiratory volume in 1 second (p < 0.001). The discriminative property of CRP was greatest during the first year of measurement and decayed over time. Comparing the highest and lowest CRP quintiles, the RR was 4.03 (95% CI 1.23 to 13.21) for 1 year mortality, 3.30 (95% CI 1.38 to 7.86) for 2 year mortality, and 1.82 (95% CI 1.22 to 2.68) for > or =5 year mortality.
Conclusions: CRP measurements provide incremental prognostic information beyond that achieved by traditional markers of prognosis in patients with mild to moderate COPD, and may enable more accurate detection of patients at a high risk of mortality.
Conflict of interest statement
Competing interests: DDS, SFM, and RW have received research funding from GlaxoSmithKline (GSK) and have received honoraria for speaking engagements from GSK and AstraZeneca.
Similar articles
-
Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis.Atherosclerosis. 2017 Apr;259:75-82. doi: 10.1016/j.atherosclerosis.2017.02.003. Epub 2017 Feb 9. Atherosclerosis. 2017. PMID: 28327451 Review.
-
Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.JAMA. 2013 Jun 12;309(22):2353-61. doi: 10.1001/jama.2013.5732. JAMA. 2013. PMID: 23757083
-
Systemic inflammation and mortality in chronic obstructive pulmonary disease.Can J Physiol Pharmacol. 2007 Jan;85(1):141-7. doi: 10.1139/y06-093. Can J Physiol Pharmacol. 2007. PMID: 17487253 Review.
-
C-reactive protein in patients with COPD, control smokers and non-smokers.Thorax. 2006 Jan;61(1):23-8. doi: 10.1136/thx.2005.042200. Epub 2005 Sep 2. Thorax. 2006. PMID: 16143583 Free PMC article.
-
N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.JAMA. 2005 Apr 6;293(13):1609-16. doi: 10.1001/jama.293.13.1609. JAMA. 2005. PMID: 15811980
Cited by
-
Implementation of the Care Bundle for the Management of Chronic Obstructive Pulmonary Disease with/without Heart Failure.J Clin Med. 2024 Mar 12;13(6):1621. doi: 10.3390/jcm13061621. J Clin Med. 2024. PMID: 38541845 Free PMC article. Review.
-
Factors Associated With Short-Term Complications After Percutaneous Endoscopic Gastrostomy Tube Insertion: A Retrospective Cohort Study.Cureus. 2024 Mar 7;16(3):e55741. doi: 10.7759/cureus.55741. eCollection 2024 Mar. Cureus. 2024. PMID: 38463403 Free PMC article.
-
Haemoglobin and C-reactive protein levels are efficient at identifying neoplasms as the most common early mortality of chronic diseases in emergency department patients.Contemp Oncol (Pozn). 2023;27(3):176-181. doi: 10.5114/wo.2023.133352. Epub 2023 Nov 30. Contemp Oncol (Pozn). 2023. PMID: 38239859 Free PMC article.
-
Systemic and Airway Epigenetic Disruptions Are Associated with Health Status in COPD.Biomedicines. 2023 Jan 5;11(1):134. doi: 10.3390/biomedicines11010134. Biomedicines. 2023. PMID: 36672643 Free PMC article.
-
Use of Laboratory Tests and Their Prognostic Value in Patients with Stable Chronic Obstructive Pulmonary Disease.Mo Med. 2022 Nov-Dec;119(6):545-552. Mo Med. 2022. PMID: 36588649 Free PMC article. Review.
References
-
- Murray C J, Lopez A D. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 19973491498–1504. - PubMed
-
- Andreassen H, Vestbo J. Chronic obstructive pulmonary disease as a systemic disease: an epidemiological perspective. Eur Respir J 200346(Suppl)2–4s. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous